Mrna Moderna Flu Vaccine Hits Goal Paving Way For Combination Shot
Bloomberg1 day
Study: Moderna's Flu Vaccine Shows 26.6% Superior Relative Efficacy
Above: A researcher works in the lab at the Moderna Inc. headquarters in Cambridge on March 26, 2024. Image copyright: Adam Glanzman/Bloomberg/Getty Images
The Spin
Narrative A
This breakthrough represents a significant advancement in flu prevention technology. The mRNA platform offers superior precision in matching circulating strains, enabling rapid pandemic response capabilities. These results validate the potential for more effective seasonal vaccines during a time when flu hospitalizations reached 15-year highs.
Narrative B
Despite positive trial results, regulatory approval faces significant headwinds under the current administration. Health Secretary Robert F. Kennedy Jr. has restructured the vaccine advisory committees, which include known critics of mRNA, creating uncertainty around approval timelines. The new panel has already demonstrated reluctance to endorse mRNA technologies.